Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates of Leishmania donovani
eLife · 2025
DOI: 10.7554/elife.102857 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Supratim Pradhan und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India. Hauptthemen laut MEDLINE: Leishmania donovani, Amphotericin B, Leishmaniasis, Visceral, Antiprotozoal Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Grants Commission India, Prime Minister's Research Fellowship, Council of Scientific and Industrial Research.
Abstract (Originalsprache)
The management of Leishmania donovani (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges due to rising drug unresponsiveness, leading to increasing treatment failures. While hypolipidemia characterizes VL, LD, a cholesterol auxotroph, relies on host lipid scavenging for its intracellular survival. The aggressive pathology, in terms of increased organ parasite load, observed in hosts infected with antimony-unresponsive-LD (LD-R) as compared to their sensitive counterparts (LD-S), highlights LD-R’s heightened reliance on host lipids. Here, we report that LD-R-infection in mice promotes fluid-phase endocytosis in the host macrophages, selectively accumulating neutral lipids while excluding oxidized-low-density lipoprotein (LDL). LD-R enhances the fusion of endocytosed LDL-vesicles with its phagolysosomal membrane and inhibits cholesterol mobilization from these vesicles by suppressing NPC-1. This provides LD-R amastigotes with excess lipids, supporting their rapid proliferation and membrane synthesis. This excess LDL-influx leads to an eventual accumulation of neutral lipid droplets around LD-R amastigotes, thereby increasing their unresponsiveness toward Amphotericin-B, a second-line amphiphilic antileishmanial. Notably, VL patients showing relapse with Amphotericin-B treatment exhibited significantly lower serum LDL and cholesterol than cured cases. Treatment with Aspirin, a lipid droplet blocker, reduced lipid droplets around LD-R amastigotes, restoring Amphotericin-B responsiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India.
- ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
ORCID-Profile: Supratim Pradhan, Budhaditya Mukherjee
Förderung
- University Grants Commission India
- Prime Minister's Research Fellowship
- Council of Scientific and Industrial Research
Zitieren
APA
Pradhan, S., Dhar, D., Manna, D., Chakraborty, S., Bhattacharyya, A., Chauhan, K., Mukherjee, R., Sen, A., Pandey, K., Das, S., & Mukherjee, B. (2025). Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates of Leishmania donovani. eLife. https://doi.org/10.7554/elife.102857
Vancouver
Pradhan S, Dhar D, Manna D, Chakraborty S, Bhattacharyya A, Chauhan K, et al. Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates of Leishmania donovani. eLife. 2025. doi:10.7554/elife.102857
BibTeX
@article{Pradhan2025,
author = {Pradhan, Supratim and Dhar, Dhruba and Manna, Debolina and Chakraborty, Shubhangi and Bhattacharyya, Arkapriya and Chauhan, Khushi and Mukherjee, Rimi and Sen, Abhik and Pandey, Krishna and Das, Soumen and Mukherjee, Budhaditya},
title = {Scrutinized lipid utilization disrupts Amphotericin-B responsiveness in clinical isolates of Leishmania donovani},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.102857}
}
EUVIMED